<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rpmj</journal-id><journal-title-group><journal-title xml:lang="ru">Research'n Practical Medicine Journal</journal-title><trans-title-group xml:lang="en"><trans-title>Research and Practical Medicine Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2410-1893</issn><publisher><publisher-name>"QUASAR", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17709/2410-1893-2024-11-2-4</article-id><article-id custom-type="edn" pub-id-type="custom">MRWPSD</article-id><article-id custom-type="elpub" pub-id-type="custom">rpmj-988</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи. Онкология, лучевая терапия</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original articles. Oncology, radiotherapy</subject></subj-group></article-categories><title-group><article-title>Тиреоидный статус у пациентов на ранних стадиях рака различной локализации</article-title><trans-title-group xml:lang="en"><trans-title>Thyroid status in patients with early stages of cancer of various localization</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2302-8271</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бандовкина</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bandovkina</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> </p><p>Бандовкина Валерия Ахтямовна – д.б.н., ведущий научный сотрудник лаборатории изучения патогенеза злокачественных опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-2302-8271" ext-link-type="uri">https://orcid.org/0000-0002-2302-8271</ext-link>, SPIN: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?id=696989" ext-link-type="uri">8806-2641</ext-link>, Author ID: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?id=696989" ext-link-type="uri">696989</ext-link>, Scopus Author ID: <ext-link xlink:href="https://www.scopus.com/authid/detail.uri?authorId=57194276288" ext-link-type="uri">57194276288</ext-link>, Researcher ID: <ext-link xlink:href="https://www.webofscience.com/wos/author/record/AAG-8708-2019" ext-link-type="uri">AAG-8708-2019</ext-link></p></bio><bio xml:lang="en"><p> </p><p>Valerija A. Bandovkina – Dr. Sci. (Biology), leading research associate at the laboratory of malignant tumor pathogenesis study, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-2302-8271" ext-link-type="uri">https://orcid.org/0000-0002-2302-8271</ext-link>, SPIN: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?spin=8806-2641" ext-link-type="uri">8806-2641</ext-link>, Author ID: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?spin=8806-2641" ext-link-type="uri">696989</ext-link>, Scopus Author ID: <ext-link xlink:href="https://www.scopus.com/authid/detail.uri?authorId=57194276288" ext-link-type="uri">57194276288</ext-link>, Researcher ID: AAG-8708-2019</p></bio><email xlink:type="simple">valerryana@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3618-6890</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Франциянц</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Frantsiyants</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p> </p><p>Франциянц Елена Михайловна – д.б.н., профессор, заместитель генерального директора по науке ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-3618-6890" ext-link-type="uri">https://orcid.org/0000-0003-3618-6890</ext-link>, SPIN: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?id=462868" ext-link-type="uri">9427-9928</ext-link>, AuthorID: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?id=462868" ext-link-type="uri">462868</ext-link>, Scopus Author ID: 55890047700, Researcher ID: <ext-link xlink:href="https://www.webofscience.com/wos/author/record/Y-1491-2018" ext-link-type="uri">Y-1491-2018</ext-link></p></bio><bio xml:lang="en"><p> </p><p>Elena M. Frantsiyants – Dr. Sci. (Biology), Professor, Deputy CEO for Science National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-3618-6890" ext-link-type="uri">https://orcid.org/0000-0003-3618-6890</ext-link>, SPIN: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?spin=9427-9928" ext-link-type="uri">9427-9928</ext-link>, AuthorID: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?spin=9427-9928" ext-link-type="uri">462868</ext-link>, Scopus Author ID: <ext-link xlink:href="https://www.scopus.com/authid/detail.uri?authorId=55890047700" ext-link-type="uri">55890047700</ext-link>, Researcher ID: Y-1491-2018</p></bio><email xlink:type="simple">super.gormon@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2328-0987</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Салатова</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Salatova</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p> </p><p>Салатова Айна Майрбековна – врач-эндокринолог ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="http://orcid.org/0000-0002-2328-0987" ext-link-type="uri">http://orcid.org/0000-0002-2328-0987</ext-link>, SPIN: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?id=1039840" ext-link-type="uri">2484-8729</ext-link>, AuthorID: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?id=1039840" ext-link-type="uri">1039840</ext-link></p></bio><bio xml:lang="en"><p> </p><p>Aina M. Salatova – MD, endocrinologist, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="http://orcid.org/0000-0002-2328-0987" ext-link-type="uri">http://orcid.org/0000-0002-2328-0987</ext-link>, SPIN: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?spin=2484-8729" ext-link-type="uri">2484-8729</ext-link>, AuthorID: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?spin=2484-8729" ext-link-type="uri">1039840</ext-link></p></bio><email xlink:type="simple">salatowaaina@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7293-2358</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Енгибарян</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Еngibaryan</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> </p><p>Енгибарян Марина Александровна – д.м.н., заведующая отделением опухолей головы и шеи ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0001-7293-2358" ext-link-type="uri">https://orcid.org/0000-0001-7293-2358</ext-link>, SPIN: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?id=318503" ext-link-type="uri">1764-0276</ext-link>, AuthorID: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?id=318503" ext-link-type="uri">318503</ext-link>, Scopus Author ID: <ext-link xlink:href="https://www.scopus.com/authid/detail.uri?authorId=57046075800" ext-link-type="uri">57046075800</ext-link></p></bio><bio xml:lang="en"><p> </p><p>Marina A. Engibaryan – Dr. Sci. (Medicine), Head of the Department of Head and Neck Tumors, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0001-7293-2358" ext-link-type="uri">https://orcid.org/0000-0001-7293-2358</ext-link>, SPIN: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?spin=1764-0276" ext-link-type="uri">1764-0276</ext-link>, AuthorID: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?spin=1764-0276" ext-link-type="uri">318503</ext-link>, Scopus Author ID: <ext-link xlink:href="https://www.scopus.com/authid/detail.uri?authorId=57046075800" ext-link-type="uri">57046075800</ext-link></p></bio><email xlink:type="simple">mar457@yandx.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5793-968X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волкова</surname><given-names>В. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Volkova</surname><given-names>V. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p> </p><p>Волкова Виктория Львовна – к.м.н., врач-онколог отделения опухолей головы и шеи ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-5793-968X" ext-link-type="uri">https://orcid.org/0000-0002-5793-968X</ext-link>, SPIN: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?id=290072" ext-link-type="uri">8289-6300</ext-link>, AuthorID: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?id=290072" ext-link-type="uri">290072</ext-link></p></bio><bio xml:lang="en"><p> </p><p>Viktoriya L. Volkova – Cand. Sci. (Medicine), MD, oncologist of the Department of Head and Neck Tumors, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-5793-968X" ext-link-type="uri">https://orcid.org/0000-0002-5793-968X</ext-link>, SPIN: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?spin=8289-6300" ext-link-type="uri">8289-6300</ext-link>, AuthorID: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?spin=8289-6300" ext-link-type="uri">290072</ext-link></p></bio><email xlink:type="simple">vikun2011@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3711-8155</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черярина</surname><given-names>Н. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Cheryarina</surname><given-names>N. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p> </p><p>Черярина Наталья Дмитриевна – врач-лаборант лаборатории изучения патогенеза злокачественных опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-3711-8155" ext-link-type="uri">https://orcid.org/0000-0002-3711-8155</ext-link>, SPIN: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?id=558243" ext-link-type="uri">2189-3404</ext-link>, Author ID: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?id=558243" ext-link-type="uri">558243</ext-link>, Scopus Author ID: <ext-link xlink:href="https://www.scopus.com/authid/detail.uri?authorId=56204439400" ext-link-type="uri">56204439400</ext-link></p></bio><bio xml:lang="en"><p> </p><p>Nataliya D. Cheryarina – MD, laboratory assistant at the Laboratory for the study of the pathogenesis of malignant tumors, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-3711-8155" ext-link-type="uri">https://orcid.org/0000-0002-3711-8155</ext-link>, SPIN: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?spin=2189-3404" ext-link-type="uri">2189-3404</ext-link>, Author ID: <ext-link xlink:href="https://www.elibrary.ru/author_profile.asp?spin=2189-3404" ext-link-type="uri">558243</ext-link>, Scopus Author ID: <ext-link xlink:href="https://www.scopus.com/authid/detail.uri?authorId=56204439400" ext-link-type="uri">56204439400</ext-link></p></bio><email xlink:type="simple">scalolas.92@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр онкологии Министерства здравоохранения Российской Федерации&lt;p&gt;&#13;
г. Ростов-на-Дону, Российская Федерация</institution></aff><aff xml:lang="en"><institution>National Medical Research Centre for Oncology&lt;p&gt;&#13;
Rostov-on-Don, Russian Federation</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>20</day><month>05</month><year>2024</year></pub-date><volume>11</volume><issue>2</issue><fpage>46</fpage><lpage>56</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бандовкина В.А., Франциянц Е.М., Салатова А.М., Енгибарян М.А., Волкова В.Л., Черярина Н.Д., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Бандовкина В.А., Франциянц Е.М., Салатова А.М., Енгибарян М.А., Волкова В.Л., Черярина Н.Д.</copyright-holder><copyright-holder xml:lang="en">Bandovkina V.A., Frantsiyants E.M., Salatova A.M., Еngibaryan M.A., Volkova V.L., Cheryarina N.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpmj.ru/rpmj/article/view/988">https://www.rpmj.ru/rpmj/article/view/988</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Определить состояние тиреоидного статуса первичных онкологических пациентов на ранних стадиях рака тела матки, рака почки, рака молочной железы, меланомы кожи и рака легкого без эндокринной патологии в анамнезе.</p></sec><sec><title>Пациенты и методы</title><p>Пациенты и методы. У 132 больных раком молочной железы, раком тела матки, раком легкого, раком почки и меланомой кожи (средний возраст пациентов 55 лет) в сыворотке крови радиоизотопным методом (РИА) определяли уровень тиреотропного гормона (ТТГ), тиреоидных гормонов (ТГ) Т4 и Т3 общих и свободных форм. Группу сравнения составили практически здоровые доноры.</p></sec><sec><title>Результаты</title><p>Результаты. Только при меланоме кожи уровень ТТГ в сыворотке крови был снижен в 1,5 раза (p &lt; 0,05). Содержание Т4 оказалось снижено в 1,4–1,7 раза (p &lt; 0,05) при раке тела матки и раке почки, но повышено у больных раком легкого и 16 % пациенток больных раком молочной железы в 1,4–1,7 раза (p &lt; 0,05). Низкий в 1,3–1,5 раза (p &lt; 0,05) уровень Т3 обнаружен при раке молочной железы, раке почки, меланоме кожи, тогда как повышенный в 1,6 раза (p &lt; 0,05) – при раке тела матки. Выявленные изменения ТГ по типу клинического гипертиреоза – возрастание в 1,8 раз (p &lt; 0,05) FT3 на фоне низкого ТТГ в крови у больных меланомой кожи, и по типу гипертироксинемии у больных раком легкого и раком молочной железы, заключающиеся в повышении концентраций Т4 и FT3, а у пациенток больных раком тела матки свободной и общей формы Т3, а также FT4, без изменения ТТГ в сыворотке крови больных могут быть связаны с особенностями злокачественной патологии, так как известно, что ТГ являются стимуляторами пролиферации и могут накапливаться в опухоли.</p></sec><sec><title>Заключение</title><p>Заключение. Развитие злокачественной опухоли даже на ранних стадиях заболевания воспринимается организмом как угрожающее гомеостазу состояние, и ответом на возникновение неоплазмы является реакция гипоталамо-гипофизарно-тиреоидной регуляторной оси, в результате чего у больных формируется синдром эутиреоидного расстройства.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose of the study</title><p>Purpose of the study. To determine the thyroid status of primary cancer patients in the early stages of uterine body cancer, kidney cancer, breast cancer, skin melanoma and lung cancer without a history of endocrine pathology.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. The content levels of thyroid-stimulating hormone (TSH), thyroid hormones (THs) T4 and T3 of total and free forms were determined in the blood serum by RIA method in 132 patients with breast cancer, uterine body cancer, lung cancer, kidney cancer and skin melanoma (average age 55 years). The comparison group consisted of practically healthy donors.</p></sec><sec><title>Results</title><p>Results. Only in skin melanoma, serum TSH levels were reduced by 1.5 times (p &lt; 0.05). The T4 content was reduced by 1.4–1.7 times (p &lt; 0.05) in uterine body cancer and kidney cancer, increased in lung cancer patients and 16 % of breast cancer patients by 1.4–1.7 times though (p &lt; 0.05). A 1.3–1.5‑fold low (p &lt; 0.05) T3 level was found in breast cancer, kidney cancer, and skin melanoma, while an 1.6‑fold increase (p &lt; 0.05) was found in uterine body cancer. The revealed changes in THs by the type of clinical hyperthyroidism are an increase of 1.8 times (p &lt; 0.05) FT3 on the background of low TSH in the blood in patients with skin melanoma, and by the type of hyperthyroxinemia in patients with lung cancer and breast cancer, consisting in increased concentrations of T4 and FT3, and with free and total T3 levels in patients uterine body cancer, as well as FT4, without changes in TSH in the blood serum of patients, may be associated with the features of malignant pathology, since it is known that THs are proliferation stimulants and can build up in tumors.</p></sec><sec><title>Conclusion</title><p>Conclusion. The development of a malignant tumor even in the early stages of the disease is perceived by the body as a threat for homeostasis and the response to the occurrence of neoplasm is the reaction of the hypothalamicpituitary-thyroid regulatory axis. As an outcome, patients develop euthyroid disorder syndrome.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>синдром эутиреоидного расстройства</kwd><kwd>тиреотропный гормон</kwd><kwd>тиреоидные гормоны</kwd><kwd>онкологические пациенты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>euthyroid disorder syndrome</kwd><kwd>thyroid stimulating hormone</kwd><kwd>thyroid hormones</kwd><kwd>cancer patients</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">финансирование данной работы не проводилось.</funding-statement><funding-statement xml:lang="en">this work was not funded.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sun Y, Xia PF, Korevaar TIM, Mustieles V, Zhang Y, Pan XF, Wang YX, Messerlian C. Relationship between Blood Trihalomethane Concentrations and Serum Thyroid Function Measures in U.S. Adults. Environ Sci Technol. 2021 Oct 19;55(20):14087–14094. https://doi.org/10.1021/acs.est.1c04008</mixed-citation><mixed-citation xml:lang="en">Sun Y, Xia PF, Korevaar TIM, Mustieles V, Zhang Y, Pan XF, Wang YX, Messerlian C. Relationship between Blood Trihalomethane Concentrations and Serum Thyroid Function Measures in U.S. Adults. Environ Sci Technol. 2021 Oct 19;55(20):14087–14094. https://doi.org/10.1021/acs.est.1c04008</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Manolis AA, Manolis TA, Melita H, Manolis AS. Subclinical thyroid dysfunction and cardiovascular consequences: An alarming wake-up call? Trends Cardiovasc Med. 2020 Feb;30(2):57–69. https://doi.org/10.1016/j.tcm.2019.02.011</mixed-citation><mixed-citation xml:lang="en">Manolis AA, Manolis TA, Melita H, Manolis AS. Subclinical thyroid dysfunction and cardiovascular consequences: An alarming wake-up call? Trends Cardiovasc Med. 2020 Feb;30(2):57–69. https://doi.org/10.1016/j.tcm.2019.02.011</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kalra S, Aggarwal S, Khandelwal D. Thyroid Dysfunction and Dysmetabolic Syndrome: The Need for Enhanced Thyrovigilance Strategies. Int J Endocrinol. 2021 Mar 29;2021:9641846. https://doi.org/10.1155/2021/9641846</mixed-citation><mixed-citation xml:lang="en">Kalra S, Aggarwal S, Khandelwal D. Thyroid Dysfunction and Dysmetabolic Syndrome: The Need for Enhanced Thyrovigilance Strategies. Int J Endocrinol. 2021 Mar 29;2021:9641846. https://doi.org/10.1155/2021/9641846</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Deng XY, Yi M, Li WG, Ye HY, Chen ZS, Zhang XD. The prevalence, hospitalization outcomes and risk factors of euthyroid sick syndrome in patients with diabetic ketosis/ketoacidosis. BMC Endocr Disord. 2023 Sep 12;23(1):195. https://doi.org/10.1186/s12902-023-01451-x</mixed-citation><mixed-citation xml:lang="en">Deng XY, Yi M, Li WG, Ye HY, Chen ZS, Zhang XD. The prevalence, hospitalization outcomes and risk factors of euthyroid sick syndrome in patients with diabetic ketosis/ketoacidosis. BMC Endocr Disord. 2023 Sep 12;23(1):195. https://doi.org/10.1186/s12902-023-01451-x</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Krug N, Bercker S, Busch T, Friese S, Jahn N, Voelker MT. Non-thyroidal Illness Syndrome (NTIS) is no independent predictor for mortality in ICU patients. BMC Anesthesiol. 2023 Mar 31;23(1):103. https://doi.org/10.1186/s12902-023-01451-x</mixed-citation><mixed-citation xml:lang="en">Krug N, Bercker S, Busch T, Friese S, Jahn N, Voelker MT. Non-thyroidal Illness Syndrome (NTIS) is no independent predictor for mortality in ICU patients. BMC Anesthesiol. 2023 Mar 31;23(1):103. https://doi.org/10.1186/s12902-023-01451-x</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hashemipour S, Shahsavari P, Kiani S, Badri M, Ghobadi A, Hadizadeh Khairkhahan SMR, et al. Wide spectrum of thyroid function tests in COVID-19: from Nonthyroidal Illness to isolated hyperthyroxinemia. Int J Endocrinol Metab. 2022;20(1):e120709. https://doi.org/10.5812/ijem.120709</mixed-citation><mixed-citation xml:lang="en">Hashemipour S, Shahsavari P, Kiani S, Badri M, Ghobadi A, Hadizadeh Khairkhahan SMR, et al. Wide spectrum of thyroid function tests in COVID-19: from Nonthyroidal Illness to isolated hyperthyroxinemia. Int J Endocrinol Metab. 2022;20(1):e120709. https://doi.org/10.5812/ijem.120709</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ashrafi S, Hatami H, Bidhendi-Yarandi R, Panahi MH. The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis. BMC Endocr Disord. 2024 Jan 2;24(1):5. https://doi.org/10.1186/s12902-023-01534-9</mixed-citation><mixed-citation xml:lang="en">Ashrafi S, Hatami H, Bidhendi-Yarandi R, Panahi MH. The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis. BMC Endocr Disord. 2024 Jan 2;24(1):5. https://doi.org/10.1186/s12902-023-01534-9</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Cristinel Badiu D, Popescu GC, Zgura A, Mercan Stanciu A, Dodot MD, Mehedintu C, et al. A prospective observational study of 42 patients with COVID-19 infection and a history of hepatitis C virus infection and thyroid disease with follow-up thyroid function and autoantibody testing. Med Sci Monit. 2021;27:e935075. https://doi.org/10.12659/msm.935075</mixed-citation><mixed-citation xml:lang="en">Cristinel Badiu D, Popescu GC, Zgura A, Mercan Stanciu A, Dodot MD, Mehedintu C, et al. A prospective observational study of 42 patients with COVID-19 infection and a history of hepatitis C virus infection and thyroid disease with follow-up thyroid function and autoantibody testing. Med Sci Monit. 2021;27:e935075. https://doi.org/10.12659/msm.935075</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Winkler F, Venkatesh HS, Amit M, Batchelor T, Demir IE, Deneen B, et al. Cancer neuroscience: State of the field, emerging directions. Cell. 2023 Apr 13;186(8):1689–1707. https://doi.org/10.1016/j.cell.2023.02.002</mixed-citation><mixed-citation xml:lang="en">Winkler F, Venkatesh HS, Amit M, Batchelor T, Demir IE, Deneen B, et al. Cancer neuroscience: State of the field, emerging directions. Cell. 2023 Apr 13;186(8):1689–1707. https://doi.org/10.1016/j.cell.2023.02.002</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lan YL, Zou S, Wang W, Chen Q, Zhu Y. Progress in cancer neuroscience. MedComm. 2023 Nov 22;4(6):e431. https://doi.org/10.1002/mco2.431</mixed-citation><mixed-citation xml:lang="en">Lan YL, Zou S, Wang W, Chen Q, Zhu Y. Progress in cancer neuroscience. MedComm. 2023 Nov 22;4(6):e431. https://doi.org/10.1002/mco2.431</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Козлова М. Б., Франциянц Е. М., Светицкий П. В., Енгибарян М. А., Пустовая И. В., Черкес М. А., Исламова Е. Ф. Системный гормональный статус и состояние метаболизма гормонов у больных раком слизистой оболочки полости рта. Успехи современного естествознания. 2015;2:68–72. https://natural-sciences.ru/ru/article/view?id=34703</mixed-citation><mixed-citation xml:lang="en">Kozlova MB, Frantsiyants EM, Svetitskiy PV, Engibaryan MA, Pustovaya IV, Cherkes MA, Islamova EF. Systemic hormonal status and hormone metabolism of patients with oral mucosa cancer. Advances in Current Natural Sciences. 2015;2:68–72. (In Russ.). https://natural-sciences.ru/ru/article/view?id=34703</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jansen HI, Boelen A, Heijboer AC, Bruinstroop E, Fliers E. Hypothyroidism: The difficulty in attributing symptoms to their underlying cause. Front Endocrinol (Lausanne). 2023 Feb 6;14:1130661. https://doi.org/10.3389/fendo.2023.1130661</mixed-citation><mixed-citation xml:lang="en">Jansen HI, Boelen A, Heijboer AC, Bruinstroop E, Fliers E. Hypothyroidism: The difficulty in attributing symptoms to their underlying cause. Front Endocrinol (Lausanne). 2023 Feb 6;14:1130661. https://doi.org/10.3389/fendo.2023.1130661</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Франциянц Е. М., Бандовкина В. А., Каплиева И. В., Трепитаки Л. К., Черярина Н. Д., Димитриади С. Н., Пржедецкий Ю. В. Влияние роста перевивной меланомы В16/F10 на функционирование гипоталамо-гипофизарно-надпочечниковой и тиреоидной осей организма у самцов и самок мышей. Известия высших учебных заведений. Северо-Кавказский регион. Естественные науки. 2017;(3-2):118–124.</mixed-citation><mixed-citation xml:lang="en">Frantsiyants EM, Bandovkina VA, Kaplieva IV, Trepitaki LK, Cheryarina ND, Dimitriadi SN, Przhedetskiy YuV. Influence of transplantable В16/F10 melanoma growth on hypothalamic-pituitary-adrenal and thyroid axes in male and female mice. Bulletin Of Higher Education Institutes. North Caucasus Region. Natural Sciences. 2017;(3-2):118–124. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Бандовкина В. А., Франциянц Е. М., Кит О. И. Нейроэндокринные и метаболические аспекты патогенеза меланомы: экспериментально-клиническое исследование. М., 2023, 327 с.</mixed-citation><mixed-citation xml:lang="en">Bandovkina VA, Frantsiyants EM, Kit OI. Neuroendocrine and metabolic aspects of melanoma pathogenesis: experimental and clinical study. Moscow,2023, 327 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Fliers E, Boelen A. An update on non-thyroidal illness syndrome. J Endocrinol Invest. 2021 Aug;44(8):1597–1607. https://doi.org/10.1007/s40618-020-01482-4</mixed-citation><mixed-citation xml:lang="en">Fliers E, Boelen A. An update on non-thyroidal illness syndrome. J Endocrinol Invest. 2021 Aug;44(8):1597–1607. https://doi.org/10.1007/s40618-020-01482-4</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Франциянц Е. М., Бандовкина В. А., Ващенко Л. Н., Тодоров С. С., Черярина Н. Д., Салатова А. М., и др. Особенности синдрома эутиреоидного расстройства у больных раком молочной железы. Исследования и практика в медицине. 2023;10(3):21–31. https://doi.org/10.17709/2410-1893-2023-10-3-2</mixed-citation><mixed-citation xml:lang="en">Frantsiyants EM, Bandovkina VA, Vashchenko LN, Todorov SS, Cheryarina ND, Salatova AM, et al. Characteristics of euthyroid sick syndrome in patients with breast cancer. Research and Practical Medicine Journal. (Issled. prakt. med.). 2023;10(3):21–31. (In Russ.). https://doi.org/10.17709/2410-1893-2023-10-3-2</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Gauthier BR, Sola-García A, Cáliz-Molina MÁ, Lorenzo PI, Cobo-Vuilleumier N, Capilla-González V, Martin-Montalvo A. Thyroid hormones in diabetes, cancer, and aging. Aging Cell. 2020 Nov;19(11):e13260. https://doi.org/10.1111/acel.13260</mixed-citation><mixed-citation xml:lang="en">Gauthier BR, Sola-García A, Cáliz-Molina MÁ, Lorenzo PI, Cobo-Vuilleumier N, Capilla-González V, Martin-Montalvo A. Thyroid hormones in diabetes, cancer, and aging. Aging Cell. 2020 Nov;19(11):e13260. https://doi.org/10.1111/acel.13260</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kit OI, Bandovkina VA, Frantsiyants EM, Kaplieva IV, Surikova EI, Neskubina IV, et al. Disorders in connections of the hypothalamic-pituitarygonadal axis in rats with Guerin's carcinoma against the background of induced hypothyroidism. Cardiometry. 2023;(27):12–20. https://doi.org/10.18137/cardiometry.2023.27.1219</mixed-citation><mixed-citation xml:lang="en">Kit OI, Bandovkina VA, Frantsiyants EM, Kaplieva IV, Surikova EI, Neskubina IV, et al. Disorders in connections of the hypothalamic-pituitarygonadal axis in rats with Guerin's carcinoma against the background of induced hypothyroidism. Cardiometry. 2023;(27):12–20. https://doi.org/10.18137/cardiometry.2023.27.1219</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Франциянц Е. М., Бандовкина В. А., Каплиева И. В., Сурикова Е. И., Нескубина И. В., Погорелова Ю. А., и др. Изменение патофизиологии роста опухоли и функциональной активности гипоталамо-гипофизарно-тиреоидной оси у крыс обоего пола при развитии карциномы Герена на фоне гипотиреоза. Южно-Российский онкологический журнал. 2022;3(4):26–39. https://doi.org/10.37748/2686-9039-2022-3-4-3</mixed-citation><mixed-citation xml:lang="en">Frantsiyants EM, Bandovkina VA, Kaplieva IV, Surikova EI, Neskubina IV, Pogorelova YuA, et al. Changes in pathophysiology of tumor growth and functional activity of the hypothalamic-pituitary-thyroid axis in rats of both sexes with the development of Guerin's carcinoma on the background of hypothyroidism. South Russian Journal of Cancer. 2022;3(4):26–39. https://doi.org/10.37748/2686-9039-2022-3-4-3</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Majos A, Sewerynek E, Grząsiak O, Ciesielski W, Hogendorf P, Hołyński J, et al. FT3 to FT4 Conversion Ratio May Be an Independent Prognostic Factor in Pancreatic Cancer Patients. Biomedicines. 2023 Dec 28;11(1):77. https://doi.org/10.3390/biomedicines11010077</mixed-citation><mixed-citation xml:lang="en">Majos A, Sewerynek E, Grząsiak O, Ciesielski W, Hogendorf P, Hołyński J, et al. FT3 to FT4 Conversion Ratio May Be an Independent Prognostic Factor in Pancreatic Cancer Patients. Biomedicines. 2023 Dec 28;11(1):77. https://doi.org/10.3390/biomedicines11010077</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Van den Berghe G. Non-Thyroidal Illness in the ICU: A Syndrome With Different Faces. Thyroid. 2014;24(10):1456–1465. https://doi.org/10.1089/thy.2014.0201</mixed-citation><mixed-citation xml:lang="en">Van den Berghe G. Non-Thyroidal Illness in the ICU: A Syndrome With Different Faces. Thyroid. 2014;24(10):1456–1465. https://doi.org/10.1089/thy.2014.0201</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Cayrol F, Sterle HA, Montesinos MDM. Editorial: Thyroid hormone actions in cancer. Front Endocrinol (Lausanne). 2023 May 25;14:1219871. https://doi.org/10.3389/fendo.2023.1219871</mixed-citation><mixed-citation xml:lang="en">Cayrol F, Sterle HA, Montesinos MDM. Editorial: Thyroid hormone actions in cancer. Front Endocrinol (Lausanne). 2023 May 25;14:1219871. https://doi.org/10.3389/fendo.2023.1219871</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Руяткина Л. А., Руяткин Д. С. Интегральный сердечно-сосудистый риск: метаболический синдром и дисфункция щитовидной железы. Сибирское медицинское обозрение. 2010;4(64):11–16.</mixed-citation><mixed-citation xml:lang="en">Ruyatkina LA, Ruyatkin DS. Integral cardiovascular risk: metabolic syndrome and thyroid dysfunction. Siberian Medical Review. 2010;4(64):11–16. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Наниева А. Р., Хутугова И. А., Джиоев И. Г., Бузоева М. Р., Берёзова Д. Т. Функционально-морфологическое состояние почек при гипо- и гипертиреозе. Современные проблемы науки и образования. 2023;(5):94. https://doi.org/10.17513/spno.32939</mixed-citation><mixed-citation xml:lang="en">Nanieva AR, Khutugova IA, Dzhioev IG, Buzoeva MR, Berezova DT. Functional and morphological state of the kidneys in hypo-and hyperthyroidism. Modern Problems of Science and Education. 2023;5:94. (In Russ.). https://doi.org/10.17513/spno.32939</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Wang K, Zhang D, Cao G, Wang C, Wang L, Zhao R, et al. A Low Free T3 to Free T4 Ratio Is Associated with Sarcopenia in Euthyroid Patients with Type 2 Diabetes Mellitus. J Diabetes Res. 2022 Aug 17;2022:2305156. https://doi.org/10.1155/2022/2305156</mixed-citation><mixed-citation xml:lang="en">Wang K, Zhang D, Cao G, Wang C, Wang L, Zhao R, et al. A Low Free T3 to Free T4 Ratio Is Associated with Sarcopenia in Euthyroid Patients with Type 2 Diabetes Mellitus. J Diabetes Res. 2022 Aug 17;2022:2305156. https://doi.org/10.1155/2022/2305156</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Urrunaga-Pastor D, Guarnizo-Poma M, Moncada-Mapelli E, Aguirre LG, Lazaro-Alcantara H, Paico-Palacios S, et al. High free triiodothyronine and free-triiodothyronine-to-free-thyroxine ratio levels are associated with metabolic syndrome in a euthyroid population. Diabetes Metab Syndr. 2018;12(2):155–161. https://doi.org/10.1016/j.dsx.2017.12.003</mixed-citation><mixed-citation xml:lang="en">Urrunaga-Pastor D, Guarnizo-Poma M, Moncada-Mapelli E, Aguirre LG, Lazaro-Alcantara H, Paico-Palacios S, et al. High free triiodothyronine and free-triiodothyronine-to-free-thyroxine ratio levels are associated with metabolic syndrome in a euthyroid population. Diabetes Metab Syndr. 2018;12(2):155–161. https://doi.org/10.1016/j.dsx.2017.12.003</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kong SH, Kim JH, Park YJ, Lee JH, Hong AR, Shin CS, Cho NH. Low free T3 to free T4 ratio was associated with low muscle mass and impaired physical performance in community-dwelling aged population. Osteoporos Int. 2020 Mar;31(3):525–531. https://doi.org/10.1007/s00198-019-05137-w</mixed-citation><mixed-citation xml:lang="en">Kong SH, Kim JH, Park YJ, Lee JH, Hong AR, Shin CS, Cho NH. Low free T3 to free T4 ratio was associated with low muscle mass and impaired physical performance in community-dwelling aged population. Osteoporos Int. 2020 Mar;31(3):525–531. https://doi.org/10.1007/s00198-019-05137-w</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
